表紙
市場調查報告書

激躁性結腸症:開發中產品分析

Irritable Bowel Syndrome - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 232842
出版日期 內容資訊 英文 160 Pages
訂單完成後即時交付
價格
激躁性結腸症:開發中產品分析 Irritable Bowel Syndrome - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 160 Pages
簡介

激躁性結腸症(IBS)是伴隨慢性或復發性免疫反應的症狀,或是消化管發炎的用語。症候有腹部的痙攣和疼痛,有血的腹瀉,體重減輕,食慾不振,及發燒等。原因有年齡,家族病史,抽煙,止痛藥等。可使用皮質類固醇,免疫抑制劑,抗生素,鎮壓藥等來治療。

本報告提供全球各國治療激躁性結腸症(IBS)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

激躁性結腸症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

激躁性結腸症的治療藥開發企業

  • 4D Pharma PLC
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Alfa Wassermann SpA
  • Allergan Plc
  • Ardelyx Inc
  • Astellas Pharma Inc.
  • CJ HealthCare Corp
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co., Ltd.
  • Eisai
  • Enterome Bioscience SA
  • GlaxoSmithKline Plc
  • Innovative Med Concepts LLC
  • Ironwood Pharmaceuticals Inc
  • Kissei藥品
  • Lexicon Pharmaceuticals Inc
  • Napo Pharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • SK Biopharmaceuticals Co Ltd
  • 大日本住友製藥
  • Synergy Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc

藥物簡介

激躁性結腸症:暫停中的計劃

激躁性結腸症:開發中止的產品

激躁性結腸症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12197IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2020, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 5, 2, 10, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Irritable Bowel Syndrome - Overview
  • Irritable Bowel Syndrome - Therapeutics Development
  • Irritable Bowel Syndrome - Therapeutics Assessment
  • Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
  • Irritable Bowel Syndrome - Drug Profiles
  • Irritable Bowel Syndrome - Dormant Projects
  • Irritable Bowel Syndrome - Discontinued Products
  • Irritable Bowel Syndrome - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Irritable Bowel Syndrome, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H1 2020
  • Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2020
  • Irritable Bowel Syndrome - Pipeline by AsiaBiome, H1 2020
  • Irritable Bowel Syndrome - Pipeline by Assembly Biosciences Inc, H1 2020
  • Irritable Bowel Syndrome - Pipeline by Axim Biotechnologies Inc, H1 2020
  • Irritable Bowel Syndrome - Dormant Projects, H1 2020
  • Irritable Bowel Syndrome - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Irritable Bowel Syndrome - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Irritable Bowel Syndrome - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Irritable Bowel Syndrome - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Irritable Bowel Syndrome, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020